Salix Pharmaceuticals Ltd., of Raleigh, N.C., reported total net product revenues for the fourth quarter of $13 million, compared to $238 million for the fourth quarter of 2013. Non-GAAP net loss for the quarter was $167 million, or $2.61 per share, far greater than the expected 25-cent-per-share loss predicted by analysts.